Health Care [ 7/12 ] | Biotechnology [ 20/73 ]
NASDAQ | Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States.
Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and provides CellTrapper technology for use in reduction of payload cellular permeability.
The company develops VIP943, an antibody drug conjugate in Phase 1 dose-escalation study for relapsed/refractory acute myeloid leukemia, higher-risk MDS, and B-cell acute lymphoblastic leukemia; VIP236, an SMDC, which is in Phase 1 dose-escalation study for the treatment of patients with advanced or metastatic solid tumors; and VIP924, an anti-CXCR5 ADC that leverages the same effector chemistry in preclinical studies for b-cell malignancies.
It has a collaboration with the National Institutes of Health for the Phase 1 dose-escalation of enitociclib, a highly selective cyclin-dependent kinase 9 inhibitor.
The company was formerly known as Vincera Pharma, Inc. and changed its name to Vincerx Pharma, Inc. in January 2021.
Vincerx Pharma, Inc. was founded in 2019 and is headquartered in San Mateo, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -3.57 Decreased by -515.41% | -0.12 Decreased by -2.87 K% |
| Mar 27, 25 | -15.22 Decreased by -6.52 K% | -3.40 Decreased by -347.65% |
| Nov 12, 24 | -0.17 Increased by +62.67% | -0.22 Increased by +21.95% |
| Aug 8, 24 | -0.05 Increased by +90.38% | -0.20 Increased by +75.00% |
| May 14, 24 | -0.58 Increased by +14.71% | -0.23 Decreased by -152.17% |
| Mar 29, 24 | -0.23 Increased by +64.62% | -0.37 Increased by +37.84% |
| Nov 14, 23 | -0.46 Increased by +42.50% | -0.46 |
| Aug 7, 23 | -0.52 Increased by +40.91% | -0.60 Increased by +13.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -5.00 M Increased by +59.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -7.99 M Decreased by -61.49% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -7.84 M Increased by +19.27% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.81 M Increased by +83.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -12.43 M Increased by +8.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.31 M Increased by +N/A% | -4.95 M Increased by +9.31% | Decreased by -376.71% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.71 M Increased by +42.37% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.15 M Increased by +35.24% | Decreased by N/A% Decreased by N/A% |